In light of the clinical success of BCR targeting, our study focuses on combinations involving BCR inhibitors, as these are already a part of clinically relevant combination approaches in CLL and other B-cell lymphomas. The gene discussed is BCR; the disease is B-cell non-Hodgkin lymphoma.